Navigation Links
Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
Date:9/28/2010

ew healthcare environment. The combined leadership team will bring vast experience in the generics space, including in product development, manufacturing and collaborative technical management.

Marvin Samson, Chairman and Chief Executive Officer of Qualitest, added, "Today's announcement brings together two highly successful businesses that I believe are an excellent fit. I am confident Qualitest's unique capabilities as a leading generics provider ideally complement Endo's diversified businesses. I am convinced that this combination will enable our management team and employees to accelerate the growth of our business and continue the important work we do here at Qualitest."  

Qualitest brings a highly qualified and experienced management team to Endo, with a track record of success in building leading and growing generics businesses. Further, Endo believes Qualitest adds important new capabilities, with the combined company having exceptional breadth and depth in the development, manufacture, distribution and sale of generic pharmaceuticals. The current Chairman and CEO of Qualitest, Marvin Samson, along with Julie McHugh, Endo's Chief Operating Officer, will lead an integration team comprised of senior leaders from both organizations focused on accelerating the growth of the combined business. Endo intends to retain Qualitest's facilities located in Huntsville, Ala. and Charlotte, N.C., as well as its own facility in Westbury, N.Y.

Endo is acquiring Qualitest Pharmaceuticals from funds advised by Apax Partners, one of the world's leading private equity investment groups.  Buddy Gumina, Partner and Co-Head of Global Healthcare at Apax, said, "We have been proud to work with the management team at Qualitest over the past three years as they have built one of the leading generics businesses in the U.S. by supplying high quality, cost effective pharmaceuticals.  Qualitest, and now Endo, represents an important part of the solution
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
(Date:12/13/2014)... INDIANAPOLIS , Dec. 12, 2014  Novo Nordisk, a ... (CGRT), today announced a multi-year extension of their partnership, that ... No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by ... Kimball, 29, from Camarillo, California ... in the history of INDYCAR to win a race at ...
(Date:12/13/2014)... Dec. 11, 2014 Research and Markets ... of the "China Chemical Pharmaceutical Industry Report, ... http://photos.prnewswire.com/prnh/20130307/600769 ... preparation and active pharmaceutical ingredient (API), and the ... generally higher than that of the API over ...
Breaking Medicine Technology:Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 2Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 3Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 4Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 5Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 6Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series 7China Chemical Pharmaceutical Industry Report, 2013-2016 2China Chemical Pharmaceutical Industry Report, 2013-2016 3
... 18 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... is developing a potential cancer drug,that seeks to ... a pre-clinical product being developed by Aida,s Shanghai,Qiaer ... the,function of extracted fragments of Vasostatin, an inhibitor ...
... CARLSBAD, Calif., April 18 Isis,Pharmaceuticals, Inc. ... of two studies,designed to assess the impact ... Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB),Conference ... in a poster,entitled "Antisense Inhibition of Apolipoprotein ...
Cached Medicine Technology:Aida Announces New Anti-Cancer Drug Under Development 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 2Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 3Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis 4
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. ... fast approaching, a new study reveals that states that routinely ... drunk drivers on their roads. The finding suggests that ... able to deter inebriated revelers from getting behind the wheel ... being passed regarding drinking and driving," said study lead author ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... Boston, MA (PRWEB) December 15, 2014 ... health management solutions, announced today that it has ... for Quality Assurance (NCQA) for its Disease Management ... obstructive pulmonary disease (COPD), coronary heart disease and ... accreditation from NCQA for Health Dialog’s Disease Management ...
(Date:12/15/2014)... 2014 Emergo Group, Inc., a medical ... in North and South America, Europe, the Middle East, ... participants for its 2015 Medical Device Industry Survey. Each ... upcoming business and market trends as well as regulatory ... targets areas including:, , Overall prospects ...
(Date:12/15/2014)... For the second year in a row, Bird Rock ... 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak came in ... 10. This is the first year that any roaster made ... on quality, value, and other aspects, including certifications and distinct ... and at $17.99 for 12-ounces, was also the most affordable ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... large proportion of Medicare expenditures for nursing home residents ... aggressive treatments that may be avoidable and of limited ... Institute for Aging Research, an affiliate of Harvard Medical ... Archives of Internal Medicine on Jan. 10, 2011. ...
... January 10, 2011 -- Previous research regarding the association ... later life suggests that mild to moderate alcohol consumption ... research has been conducted on subjects already rather elderly ... published in the December issue of the Journal ...
... MONDAY, Jan. 10 (HealthDay News) -- The H1N1 swine flu ... a vaccine that can protect people against multiple strains of ... were infected with the H1N1 virus and recovered had a ... variety of flu strains. The virus matched typical influenza ...
... MONDAY, Jan. 10 (HealthDay News) -- Patients given cholesterol-lowering drugs ... the brain may be at an increased risk of having ... well-known that statins help reduce the risk of heart disease ... in the brain. However, whether statins also benefit patients who ...
... quintessentially masculine, women in their fertile phase are more ... paired with George Clooney types. But women with ... their partners, a recent study co-authored by a University ... man,s intelligence has no effect on the extent to ...
... found that a protein that plays an important role in ... additional mechanisms that cause it to promote atherosclerosis, or clogging ... issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology ... antioxidant therapies have not yielded more positive results. ...
Cached Medicine News:Health News:Aggressive care raises Medicare costs in end-stage dementia 2Health News:Aggressive care raises Medicare costs in end-stage dementia 3Health News:Abstinence, heavy drinking, binge drinking associated with increased risk of cognitive impairment 2Health News:People Who Recovered From H1N1 Offer Clues to Better Vaccine 2Health News:Statins May Be Harmful After Stroke 2Health News:Statins May Be Harmful After Stroke 3Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Protein thought to protect against oxidative stress also promotes clogging of arteries 2
Stainless Steel. Sterile. 2 pieces/box...
... attributes of the IMMULITE 2000, the IMMULITE ... Logic Driven Incubation (LDI). Using a newly ... be formatted for optimal performance with the ... assays, such as Siemens Diagnostics' cardiac biomarkers ...
... The SMS is a robotic sample feeder that ... systems via a robotic arm and the SMS ... 200 tubes and compatibility with clinical chemistry system ... make the SMS a practical and affordable solution ...
The properties of titanium alloy have been combined with a uniquely designed reverse radial tapping flute to produce a state-of-the-art fracture fixation system....
Medicine Products: